Zymeworks Inc
NYSE:ZYME
Zymeworks Inc
NYSE:ZYME
Price:
8.26 USD
1.85%
Market Closed
Updated:
Apr 29, 2024
Section:
Relative Value
The Relative Value of one
ZYME
stock under the Base Case scenario is
15.04
USD.
Compared to the current market price of 8.26 USD,
Zymeworks Inc
is
Undervalued by 45%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ZYME
Relative Value
Base Case
15.04
USD
Undervaluation 45%
Valuation Multiples
Multiples Across Competitors
ZYME Competitors Multiples
Zymeworks Inc Competitors
Zymeworks Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Zymeworks Inc
NYSE:ZYME
|
584.5m USD | 7.7 | -4.9 | -1.6 | -1.5 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 5.2 | 58.5 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.2B USD | 5.2 | 21.8 | 16.2 | 24.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102B USD | 10.3 | 28.2 | 22.5 | 23.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.7B USD | 7.5 | 24.7 | 16.3 | 18 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.9B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.9B USD | 3.1 | 14.6 | 8 | 10.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.4B USD | 6.2 | -9 | -9.5 | -8.1 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.2 | 27.2 | 14.7 | 18.2 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.1T KRW | 17.5 | 71.1 | 43.5 | 59.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
